Cassotide

Cassotide (Bicalutamide 50 mg) — Celon Labs non-steroidal anti-androgen for advanced prostate cancer. Hormonal therapy backbone with LHRH agonist or as monotherapy in selected cases.

SKU: Cassotide Categories: Anti Cancer Medication, Category Overview, Chronic Conditions

✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026

Encrypted checkout

Crypto pays 10% less

Discreet worldwide delivery

1,400+ customers · 50+ countries

Quick Answer

Cassotide — Bicalutamide 50 mg (Celon Laboratories). Non-steroidal androgen receptor antagonist for advanced prostate cancer — usually combined with LHRH agonist/antagonist for combined androgen blockade, or as monotherapy in selected cases.

What you get with MedsBase:

WHO-GMP certified manufacturer
Discreet plain-envelope packaging
Worldwide shipping
Rated by 1,400+ customers (read reviews)

📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.

Why order from MedsBase

Cassotide ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.

⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.

Hepatotoxicity
Bicalutamide can cause severe hepatic injury. Baseline LFTs; recheck at 1 month and every 3 months in the first year. Stop immediately if jaundice, dark urine, or pruritus develops or LFTs >2.5× ULN.

Frequently Asked Questions

When is this used?

Non-steroidal androgen receptor antagonist for advanced prostate cancer — usually combined with LHRH agonist/antagonist for combined androgen blockade, or as monotherapy in selected cases.

Side effects to watch?

Hot flushes, gynaecomastia, fatigue, sexual dysfunction (anti-androgen class effect). Drug-specific monitoring as outlined in the safety boxes above.

Drug interactions?

Vary by molecule — abiraterone is CYP3A4 substrate; bicalutamide is CYP3A4 substrate. Always disclose all medications. Strong CYP3A4 inhibitors/inducers significantly affect levels.

When should it be stopped?

On disease progression, intolerable toxicity, or successful response with planned treatment break. Always specialist-decided — abrupt cessation can result in transient PSA rise (withdrawal response) which is generally not concerning.

PSA monitoring?

PSA every 1-3 months while on therapy. Rising PSA on castration suggests castration-resistance — may need switch to second-line agents (abiraterone, enzalutamide, docetaxel).

Combined androgen blockade?

LHRH agonist (goserelin, leuprolide) + bicalutamide is a common combination. Maximal androgen blockade has modest survival benefit over LHRH alone.

Bone health?

Long-term androgen deprivation accelerates bone loss. Add a bisphosphonate (zoledronic acid) or denosumab in osteopenia/osteoporosis. Calcium and vitamin D supplementation.

Pregnancy?

Anti-androgens are teratogenic — partners must use effective contraception during therapy. Most relevant for younger men with localised disease.

What if I miss a dose?

Take when you remember if same day; otherwise skip. Specialist may have specific guidance for missed doses depending on regimen.

Cardiovascular monitoring?

Mandatory for fosfestrol; advised for abiraterone (BP, fluid retention, electrolytes); routine for bicalutamide (occasional CV review).

Other Cancer & Anti-Androgen Therapy

Calutide — bicalutamide 50 mg — alternative anti-androgen brand
Xbira — abiraterone 250 mg — CYP17 inhibitor for mCRPC
Honvan — fosfestrol 120 mg — diethylstilbestrol diphosphate
Estramustine — estramustine phosphate — alkylator for hormone-refractory disease
Zoldria — zoledronic acid IV for bone metastases

Medical Disclaimer: Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.